With reference to point no. 2 of Annexure 1 of letter nos. NLL/CS/2024-438 dated November 22, 2024, and NLL/CS/2024-476 dated April 04, 2025, vide which the Company had informed pending Litigation(s) as required under Regulation 30 of the LODR Regulations. Pursuant to : Regulation 30 of the Securities and Exchange of Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, and as amended by Circular dated March 28, 2025, Nectar Lifesciences has informed that it enclosed necessary disclosures in prescribed format for details/ updation of Litigation and/ or orders passed by any regulatory authority or judicial body as per Annexure-A.
The above information is a part of company’s filings submitted to BSE.
